HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 322 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $1,061,504 | -45.7% | 26,094 | -50.7% | 0.10% | -49.3% |
| Q4 2023 | $1,956,145 | +26.7% | 52,926 | +31.0% | 0.21% | +10.7% |
| Q3 2023 | $1,543,471 | +178.2% | 40,405 | +162.6% | 0.19% | +167.1% |
| Q2 2023 | $554,901 | -79.0% | 15,384 | -77.8% | 0.07% | -76.7% |
| Q1 2023 | $2,646,300 | +24.1% | 69,293 | +84.9% | 0.30% | +23.5% |
| Q4 2022 | $2,132,953 | +341.6% | 37,486 | +209.5% | 0.24% | +367.3% |
| Q1 2022 | $483,000 | -86.9% | 12,113 | -86.6% | 0.05% | -81.6% |
| Q3 2021 | $3,690,000 | +344.6% | 90,705 | +355.6% | 0.28% | +293.1% |
| Q1 2021 | $830,000 | -22.0% | 19,907 | -50.8% | 0.07% | +5.9% |
| Q3 2020 | $1,064,000 | +20.0% | 40,490 | +22.4% | 0.07% | -16.0% |
| Q2 2020 | $887,000 | +124.0% | 33,078 | +48.1% | 0.08% | +237.5% |
| Q4 2019 | $396,000 | – | 22,335 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,816,162 | $195,784,000 | 9.33% |
| BB BIOTECH AG | 5,846,564 | $57,764,000 | 2.74% |
| QVT Financial LP | 4,556,090 | $45,014,000 | 2.44% |
| Parametrica Management Ltd | 29,578 | $292,000 | 2.21% |
| SECTORAL ASSET MANAGEMENT INC | 4,389,682 | $43,370,000 | 1.84% |
| Belmont Global Advisors, Inc. | 257,000 | $2,539,000 | 1.83% |
| HARVEY CAPITAL MANAGEMENT INC | 394,550 | $3,898,000 | 1.40% |
| Lombard Odier Asset Management (USA) Corp | 1,350,000 | $13,338,000 | 0.70% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 6,199,685 | $61,253,000 | 0.63% |
| Callan Capital, LLC | 199,230 | $1,968,000 | 0.53% |